Compare Amylx Pharmaceuticals Inc (AMLX) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Bank of Nova Scotia — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Bank of Nova Scotia trades at $87.59 (market cap $107.21B). The key difference: Bank of Nova Scotia is far larger — about 54.1× Amylx Pharmaceuticals Inc's market cap, and Bank of Nova Scotia pays a 3.67% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BNS | |
|---|---|---|
Market Cap | $1.98B | $107.21B |
Sector | Health | Financials |
52-Week High | $18.70 | $87.59 |
52-Week Low | $7.64 | $54.50 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
BNS trades at $87.59, up 1.78% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.47, exceeding expectations, and maintains a net income margin of 24.86%. Recent news highlights dividend strength and the acquisition of MapleMark Bank to bolster growth. Analyst consensus is 53% buy, with a P/E of 17.15 indicating reasonable valuation.
Outlook is positive due to consistent earnings performance and strategic acquisitions, but risks include high debt levels and economic sensitivity. The stock offers income appeal with a $1.14 dividend, yet investors should monitor credit provisions amid soft economic conditions noted in Q2 2026 reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
